Menu
Recruiting NCT07500181

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

Phase I Interventional Healthy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: BAL2420 or placebo, BAL2420 or placebo, BAL2420 or placebo.
Who it may be relevant to
Registry conditions: Healthy. Basic parameters: 18 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Netherlands
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A First-in-Human, Randomized, Dose-escalation, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, and Pharmacokinetics of BAL2420 Administered to Healthy Adult Subjects

Overview

BAL2420 (also known as BAL0302420) is being developed as an antibacterial agent for the treatment of severe infections caused by Gram-negative bacteria. In this study, the sponsor aims to investigate the safety, tolerability and pharmacokinetics (PK) of BAL2420 following administration of single ascending doses (Part A) and multiple ascending doses (Parts B and C) in healthy adult volunteers. In all parts of the study, in each cohort, a different dose of study drug is to be investigated against a matched placebo in a randomized and double-blind manner.

Interventions

  • Drug BAL2420 or placebo
    Single ascending dose administration (SAD)
  • Drug BAL2420 or placebo
    Multiple-ascending dose (MAD)
  • Drug BAL2420 or placebo
    MAD

Primary outcome measures

  • Number of participants reporting adverse events (AEs) in Part A [Time frame: From screening until Day 10]
  • Number of participants with abnormal electrocardiograms QT Interval in Part A [Time frame: From screening until Day 10]
  • Number of participants reporting adverse events (AEs) in Part B and C [Time frame: From screening until Day 14]
  • Number of participants with abnormal ECG QT Interval in Part B and C [Time frame: From screening until Day 14]

Eligibility criteria

Inclusion criteria

  • Body mass index: 18.0 to 30.0 kg/m2, inclusive, at screening
  • Total body weight: > 50 kg at screening

Exclusion criteria

  • Any uncontrolled or active major systemic disease,
  • Active infection
  • Acute illness within 5 days prior to the first study drug administration that, in the opinion of the Investigator, may impact safety assessments.
  • Clinically-significant physical examination, vital signs, laboratory safety tests, or ECG abnormalities
  • History of risk factors for QT prolongation or Torsades de Pointes
  • QTcF (Fridericia's corrected QT interval) > 450 msec (males) and > 470 msec (females) at screening.
  • Receipt of prescribed medication other than hormonal contraceptives within the 30 days prior to admission to the clinical site.
  • Receipt of over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g., St. John's wort) within 14 days prior to admission to the clinical site.
  • History of relevant drug and/or food allergies, particularly to antibiotics.
  • History of tobacco use or e-cigarette within the past 6 months prior to the first study drug administration.
  • History of alcohol abuse or drug addiction (including soft drugs like cannabis products) within 12 months prior to screening.
  • Average intake of more than 24 units of alcohol per week: one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits.
  • Positive screen for hepatitis B surface antigen, hepatitis B core antibodies, hepatitis C virus antibodies, human immunodeficiency virus 1 and 2 antibodies, or syphilis at screening. Note: Hepatitis B vaccination is allowed.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Basic science

Study locations

Netherlands · 1 center
  • ICON Early Clinical & Bioanalytical Solutions — Groningen

Identifiers

NCT: NCT07500181 · BAL2420-CP-101 · 75A50122C00028 · 2025-523108-59-00

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗